康芝藥業(300086.SZ)完成註銷109.35萬份股票期權
格隆匯12月16日丨康芝藥業(300086.SZ)公佈,公司於2019年12月4日召開第四屆董事會第二十八次會議和第四屆監事會第二十七次會議審議通過《關於註銷2018年股票期權激勵計劃部分股票期權的議案》,鑑於原19名激勵對象因離職、協議解除勞動合同的原因不再符合激勵條件,根據公司《2018年股票期權激勵計劃(草案)》的相關規定,對19名不符合激勵條件的激勵對象已獲授但尚未行權的109.35萬份股票期權進行註銷。
公司此次註銷的股票期權共計109.35萬份,其中註銷首次授予尚未行權的股票期權89.35萬份,期權簡稱:康芝JLC1,期權代碼:036316;註銷預留部分授予尚未行權的股票期權20萬份,期權簡稱:康芝JLC2,期權代碼:036328。
經公司申請,中國證券登記結算有限責任公司深圳分公司審核確認,上述109.35萬份股票期權的註銷事宜已於2019年12月16日辦理完畢。
此次註銷後,公司2018年股票期權激勵計劃已獲授股票期權減少至1040.45萬份(其中首次授予股票期權減少至860.45萬份,預留部分授予股票期權減少至180萬份),激勵對象人數減至68人(其中首次授予的激勵對象人數減至57人,預留部分授予的激勵對象人數減至11人)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.